Biotech Values

[mcbio]

I think the stock has a very good risk/reward over the next year. BG12 pro-drug will potentially be a substantial driver, and the rest of their pipeline is decent as well.

I remain a holder and added to my position in the 5's.

I agree with your thoughts and will continue to hold. If I get the chance, I will consider adding as well. XNPT is guiding for release of the top-line Phase 2b results of XP21279, the Parkinson's treatment, by the end of next month. That could potentially serve as another near-term catalyst.